Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1516) 1516
Publication (216) 216
Book Chapter (25) 25
Book Review (17) 17
Conference Proceeding (11) 11
Dissertation (2) 2
Magazine Article (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
telaprevir (1500) 1500
index medicus (1020) 1020
humans (985) 985
boceprevir (709) 709
hepatitis c (695) 695
ribavirin (654) 654
hepatitis c virus (617) 617
hepatitis c, chronic - drug therapy (594) 594
antiviral agents - therapeutic use (569) 569
gastroenterology & hepatology (529) 529
male (528) 528
female (495) 495
hepacivirus - genetics (482) 482
middle aged (459) 459
drug therapy, combination (415) 415
genotype (407) 407
interferon (382) 382
adult (352) 352
treatment outcome (349) 349
ribavirin - therapeutic use (339) 339
hepatitis (324) 324
peginterferon (320) 320
protease inhibitors (312) 312
hepacivirus - drug effects (304) 304
virus-infection (294) 294
interferon-alpha - therapeutic use (285) 285
aged (269) 269
hepatitis c, chronic - virology (253) 253
pharmacology & pharmacy (253) 253
therapy (250) 250
plus ribavirin (249) 249
infectious diseases (246) 246
genotype 1 infection (241) 241
oligopeptides - therapeutic use (241) 241
antiviral agents - adverse effects (239) 239
virology (239) 239
antiviral agents - administration & dosage (238) 238
hepatitis c - drug therapy (238) 238
antiviral agents (231) 231
polyethylene glycols - therapeutic use (230) 230
pegylated interferon (223) 223
hcv (222) 222
proline - analogs & derivatives (222) 222
biological response modifiers (217) 217
infection (210) 210
health aspects (209) 209
sustained virological response (205) 205
care and treatment (193) 193
proteases (184) 184
drug therapy (182) 182
recombinant proteins - therapeutic use (177) 177
genetic aspects (166) 166
analysis (164) 164
chronic hepatitis-c (163) 163
sofosbuvir (163) 163
gastroenterology and hepatology (158) 158
ribavirin - administration & dosage (157) 157
chronic hepatitis c (152) 152
viral load (151) 151
virus diseases (151) 151
antiviral agents - pharmacology (150) 150
proline - therapeutic use (144) 144
protease inhibitor (134) 134
cirrhosis (130) 130
interferon-alpha - administration & dosage (127) 127
protease inhibitors - therapeutic use (126) 126
genotype 1 (124) 124
liver cirrhosis (124) 124
young adult (124) 124
rna, viral - blood (123) 123
triple therapy (122) 122
oligopeptides - adverse effects (121) 121
peginterferon alpha-2a (119) 119
simeprevir (119) 119
combination (117) 117
liver (117) 117
hepatitis c - virology (115) 115
genotype & phenotype (113) 113
microbiology (113) 113
polyethylene glycols - administration & dosage (113) 113
hiv (112) 112
viral nonstructural proteins - antagonists & inhibitors (112) 112
virus (112) 112
hepacivirus - isolation & purification (110) 110
hepatology (109) 109
combination therapy (107) 107
drug resistance, viral (105) 105
treatment-naive patients (105) 105
medicine, general & internal (103) 103
oligopeptides - administration & dosage (100) 100
anemia (98) 98
antiviral therapy (98) 98
resistance (97) 97
infections (96) 96
ribavirin - adverse effects (96) 96
hepacivirus - classification (93) 93
chronic hcv infection (92) 92
rna (92) 92
viral nonstructural proteins - genetics (92) 92
abridged index medicus (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1405) 1405
Spanish (51) 51
Hungarian (20) 20
German (19) 19
Japanese (17) 17
French (16) 16
Russian (7) 7
Czech (5) 5
Turkish (3) 3
Korean (2) 2
Croatian (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Solid dispersions of telaprevir with improved solubility prepared by co-milling: formulation, physicochemical characterization, and cytotoxicity evaluation
by Xiong, Xinnuo and Zhang, Man and Hou, Quan and Tang, Peixiao and Suo, Zili and Zhu, Yujie and Li, Hui
Materials Science & Engineering C, ISSN 0928-4931, 12/2019, Volume 105, p. 110012
Telaprevir (TVR) is typically a poorly soluble drug with an extremely low bioavailability of 1.7%. Polymorph modifications cannot improve the solubility of TVR... 
Polymer, Solubility | Solid dispersion | Cytotoxicity | Telaprevir | Dissolution
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Aspectos bioquímicos y farmacológicos de telaprevir
by Andrade, Raúl J and García-Samaniego, Javier
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 07/2013, Volume 31, pp. 2 - 6
Telaprevir es el primero de una generación de medicamentos basados en ensamblar andamiajes moleculares con enzimas codificadas por el virus de la hepatitis C,... 
Telaprevir metabolism | Inhibición NS3-4A | Telaprevir pharmacokinetics | CYP3A4 inhibition | Inhibición CYP3A4 | NS3-4A inhibition | Metabolismo de telaprevir | Farmacocinética de telaprevir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Editorial commentary: Does HIV remain a risk factor for achieving sustained virologic response under direct acting antiviral-based modern hepatitis C virus therapy?
by Rockstroh, Jürgen Kurt
Clinical Infectious Diseases, ISSN 1058-4838, 12/2014, Volume 59, Issue 12, pp. 1777 - 1778
HIV | interferon | DAA | telaprevir | hepatitis C
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial
by Sulkowski, Mark S and Asselah, Tarik and Lalezari, Jacob and Ferenci, Peter and Fainboim, Hugo and Leggett, Barbara and Bessone, Fernando and Mauss, Stefan and Heo, Jeong and Datsenko, Yakov and Stern, Jerry O and Kukolj, George and Scherer, Joseph and Nehmiz, Gerhard and Steinmann, Gerhard G and Böcher, Wulf O
Hepatology, ISSN 0270-9139, 06/2013, Volume 57, Issue 6, pp. 2143 - 2154
Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.... 
NONRESPONSE | TELAPREVIR | THERAPY | HEPATITIS-C VIRUS | PEGINTERFERON ALPHA-2A | BI 201335 | PHARMACOKINETICS | PROTEASE INHIBITOR BI201335 | 1 INFECTION | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
by Coilly, Audrey and Roche, Bruno and Dumortier, Jérôme and Leroy, Vincent and Botta-Fridlund, Danielle and Radenne, Sylvie and Pageaux, Georges-Philippe and Si-Ahmed, Si-Nafaa and Guillaud, Olivier and Antonini, Teresa Maria and Haïm-Boukobza, Stéphanie and Roque-Afonso, Anne-Marie and Samuel, Didier and Duclos-Vallée, Jean-Charles
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 60, Issue 1, pp. 78 - 86
Background & Aims: Protease inhibitors (PI) with peginterferon/ ribavirin have significantly improved SVR rates in HCV G1 patients. Their use to treat HCV... 
Boceprevir | Protease inhibitors | Early virological response | HCV recurrence | Sustained virological response | Telaprevir | Drug-drug interaction | Liver transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per Sustained Virologic Response
by Bichoupan, Kian and Martel-Laferriere, Valerie and Sachs, David and Ng, Michel and Schonfeld, Emily A and Pappas, Alexis and Crismale, James and Stivala, Alicia and Khaitova, Viktoriya and Gardenier, Donald and Linderman, Michael and Perumalswami, Ponni V and Schiano, Thomas D and Odin, Joseph A and Liu, Lawrence and Moskowitz, Alan J and Dieterich, Douglas T and Branch, Andrea D
Hepatology (Baltimore, Md.), ISSN 0270-9139, 10/2014, Volume 60, Issue 4, pp. 1187 - 1195
costs | real-world | HCV | telaprevir | SVR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients : A Real-World Retrospective Cohort Study
by Maiko Akutagawaa and Kazuki Idea and b and c and Yohei Kawasakia and Mie Yamanakaa and Ryo Iketania and Hiroshi Yamadaa and Naohiko Masakid and bDepartment of Pharmacoepidemiology and Kyoto University and Graduate School of Pharmaceutical Sciences and cCenter for the Promotion of Interdisciplinary Education and Research and University of Shizuoka and National Center for Global Health and Medicine and Graduate School of Medicine and Public Health and aDepartment of Drug Evaluation & Informatics and dLaboratory Testing Department
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 9, pp. 1525 - 1529
To compare the rate of treatment discontinuation due to adverse events for telaprevir-based triple (T/PR) and pegylated interferon-alfa-2b and ribavirin (PR)... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Drug-induced hypersensitivity syndrome by triple therapy of peginterferon alpha2b, ribavirin and telaprevir in double-positive patient for HBV and HCV
by Takagi, Hitoshi and Hoshino, Takashi and Naganuma, Atsushi and Koitabashi, Eri and Uehara, Sanae and Sakamoto, Naomi and Kudo, Tomohiro and Ryusaki, Keiichirou and Kakizaki, Satoru and Okamoto, Hiroaki
Hepato-Gastroenterology, ISSN 0172-6390, 10/2013, Volume 60, Issue 127, pp. 1557 - 1560
DIHS | HCV | Interferon | Telaprevir | HBV
Journal Article
Details down arrow
9. Full Text Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C : A Real-World Retrospective Cohort Study
by Kazuki Idea and b and c and Yohei Kawasakia and Ryo Iketanic and Naohiko Masakid and Kyoto University and Graduate School of Pharmaceutical Sciences and University of Shizuoka and National Center for Global Health and Medicine and Graduate School of Medicine and Public Health and aDepartment of Pharmacoepidemiology and dThe Research Center for Hepatitis and Immunology and cDepartment of Drug Evaluation & Informatics and bCenter for the Promotion of Interdisciplinary Education and Research
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 5, pp. 645 - 649
In this study, a nationwide database was used to identify the risk factors for treatment discontinuation due to adverse events during telaprevir,... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
by Afdhal, Nezam and Zeuzem, Stefan and Kwo, Paul and Chojkier, Mario and Gitlin, Norman and Puoti, Massimo and Romero-Gomez, Manuel and Zarski, Jean-Pierre and Agarwal, Kosh and Buggisch, Peter and Foster, Graham R and Bräu, Norbert and Buti, Maria and Jacobson, Ira M and Subramanian, G. Mani and Ding, Xiao and Mo, Hongmei and Yang, Jenny C and Pang, Phillip S and Symonds, William T and McHutchison, John G and Muir, Andrew J and Mangia, Alessandra and Marcellin, Patrick and ION-1 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
In this trial, previously untreated patients with hepatitis C virus genotype 1 infection were randomly assigned to 12 or 24 weeks of ledipasvir and sofosbuvir,... 
MEDICINE, GENERAL & INTERNAL | TELAPREVIR | THERAPY | HEPATITIS | BOCEPREVIR | RIBAVIRIN | COMBINATION | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Viral Load | Young Adult | Aged, 80 and over | Adult | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Drug Administration Schedule | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Aged | Sofosbuvir | Headache | Chronic infection | Fatigue | Infections | Nausea | Patients | Ribavirin | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon | Hepatitis C | Drug therapy | Genotypes | Medicaments antivírics | Antiviral agents | Hepatitis C virus | Virus de l'hepatitis C | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
by Kumada, Hiromitsu and Suzuki, Yoshiyuki and Ikeda, Kenji and Toyota, Joji and Karino, Yoshiyasu and Chayama, Kazuaki and Kawakami, Yoshiiku and Ido, Akio and Yamamoto, Kazuhide and Takaguchi, Koichi and Izumi, Namiki and Koike, Kazuhiko and Takehara, Tetsuo and Kawada, Norifumi and Sata, Michio and Miyagoshi, Hidetaka and Eley, Timothy and McPhee, Fiona and Damokosh, Andrew and Ishikawa, Hiroki and Hughes, Eric
Hepatology, ISSN 0270-9139, 06/2014, Volume 59, Issue 6, pp. 2083 - 2091
All‐oral combinations of direct‐acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly... 
PROTEASE INHIBITOR | VIRUS-INFECTION | TELAPREVIR | THERAPY | EFFICACY | BMS-650032 | SOFOSBUVIR | CHRONIC HEPATITIS-C | BOCEPREVIR | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | Isoquinolines - adverse effects | Humans | Imidazoles - adverse effects | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Isoquinolines - blood | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Young Adult | Imidazoles - blood | Sulfonamides - blood | Sulfonamides - therapeutic use | Treatment Failure | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Adult | Female | Aged | Imidazoles - therapeutic use | Drug Therapy, Combination | Genotype & phenotype | Interferon | Infections | Drug therapy | Hepatology | Rapid Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
by Lawitz, Eric, Prof and Poordad, Fred F, Prof and Pang, Phillip S, MD and Hyland, Robert H, DPhil and Ding, Xiao, PhD and Mo, Hongmei, PhD and Symonds, William T, PharmD and McHutchison, John G, MD and Membreno, Fernando E, MD
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9916, pp. 515 - 523
Summary Background Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of contraindications such as... 
Internal Medicine | ANTIVIRAL AGENTS | ALPHA-2A | MEDICINE, GENERAL & INTERNAL | INTERFERON | TELAPREVIR | DOUBLE-BLIND | TRIPLE THERAPY | BOCEPREVIR | INHIBITOR | Uridine Monophosphate - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - analogs & derivatives | Female | Fluorenes - administration & dosage | RNA, Viral - metabolism | Hepatitis C, Chronic - genetics | Protease Inhibitors - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Sofosbuvir | Antiviral agents | Hepatitis C | Drug therapy | Patient outcomes | Hepatitis | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Risk factors for treatment discontinuation caused by adverse events when using telaprevir, peginterferon, and ribavirin to treat chronic hepatitis C: A real-world retrospective cohort study
by Ide, Kazuki and Kawasaki, Yohei and Iketani, Ryo and Masaki, Naohiko
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017
In this study, a nationwide database was used to identify the risk factors for treatment discontinuation due to adverse events during telaprevir,... 
regional differences | ribavirin | telaprevir | nationwide database | hepatitis C | interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
by Lawitz, Eric, Prof and Sulkowski, Mark S, Prof and Ghalib, Reem, MD and Rodriguez-Torres, Maribel, MD and Younossi, Zobair M, Prof and Corregidor, Ana, MD and DeJesus, Edwin, MD and Pearlman, Brian, Prof and Rabinovitz, Mordechai, Prof and Gitlin, Norman, MD and Lim, Joseph K, MD and Pockros, Paul J, MD and Scott, John D, MD and Fevery, Bart, MSc and Lambrecht, Tom, MSc and Ouwerkerk-Mahadevan, Sivi, PhD and Callewaert, Katleen, MSc and Symonds, William T, PharmD and Picchio, Gaston, PhD and Lindsay, Karen L, MD and Beumont, Maria, MD and Jacobson, Ira M, Prof
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Summary Background Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TELAPREVIR | PHASE-3 TRIAL | DOUBLE-BLIND | BOCEPREVIR | HCV INFECTION | PEGINTERFERON | SVR | ALPHA 2A | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Simeprevir | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Male | Reference Values | Polyethylene Glycols - therapeutic use | Dose-Response Relationship, Drug | Adult | Female | Drug Therapy, Combination | Liver Function Tests | Severity of Illness Index | Drug Administration Schedule | Risk Assessment | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Sulfonamides - therapeutic use | Heterocyclic Compounds, 3-Ring - therapeutic use | Uridine Monophosphate - analogs & derivatives | Hepatitis C, Chronic - genetics | Sofosbuvir | Hepatitis | Genotype & phenotype | Liver diseases | Biopsy | Infections | Drug therapy | Liver cirrhosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
by Sulkowski, Mark S and Gardiner, David F and Rodriguez-Torres, Maribel and Reddy, K. Rajender and Hassanein, Tarek and Jacobson, Ira and Lawitz, Eric and Lok, Anna S and Hinestrosa, Federico and Thuluvath, Paul J and Schwartz, Howard and Nelson, David R and Everson, Gregory T and Eley, Timothy and Wind-Rotolo, Megan and Huang, Shu-Pang and Gao, Min and Hernandez, Dennis and McPhee, Fiona and Sherman, Diane and Hindes, Robert and Symonds, William and Pasquinelli, Claudio and Grasela, Dennis M and AI444040 Study Grp and AI444040 Study Group
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 211 - 221
In this study, once-daily treatment with oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | REPLICATION COMPLEX INHIBITOR | TELAPREVIR | PEGINTERFERON ALPHA-2A | CHRONIC HEPATITIS-C | DOUBLE-BLIND | VIRUS EPIDEMIOLOGY | RIBAVIRIN | HEALTH BURDEN | COMBINATION | Humans | Middle Aged | Hepacivirus - genetics | Male | Young Adult | Adult | Female | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | RNA, Viral - analysis | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Care and treatment | Research | Drug therapy, Combination | Hepatitis C | Headache | Antiretroviral drugs | Mortality | Chronic infection | Fatigue | Infections | Nausea | Proteinase inhibitors | Ribonucleic acid--RNA | Patients | RNA-directed RNA polymerase | Ribavirin | Nucleotide analogs | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
by Ghany, Marc G and Nelson, David R and Strader, Doris B and Thomas, David L and Seeff, Leonard B and American Association for Study of Liver Diseases
Hepatology, ISSN 0270-9139, 10/2011, Volume 54, Issue 4, pp. 1433 - 1444
SUSTAINED VIROLOGICAL RESPONSE | GENETIC-VARIATION | IL28B | PLUS RIBAVIRIN | TELAPREVIR | PEGINTERFERON ALPHA-2A | VIRAL RESPONSE | FOLLOW-UP | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | HCV INFECTION | Hepacivirus - drug effects | Recurrence | Prognosis | Proline - analogs & derivatives | Risk Assessment | Antiviral Agents - therapeutic use | United States | Humans | Drug Resistance, Viral | Hepatitis C, Chronic - physiopathology | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Oligopeptides - therapeutic use | Randomized Controlled Trials as Topic - standards | Proline - therapeutic use | Societies, Medical | Female | Hepatitis C, Chronic - genetics | Protease Inhibitors - therapeutic use | AASLD Practice Guideline
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights